Lyell Immunopharma, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Lyell Immunopharma, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2020 to Q3 2024.
  • Lyell Immunopharma, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $36.7M, a 9.71% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $36.7M -$3.94M -9.71% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $37.7M -$3.82M -9.19% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $38.7M -$3.7M -8.72% Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $39.7M -$3.58M -8.28% Dec 31, 2023 10-Q 2024-11-07
Q3 2023 $40.6M -$3.48M -7.9% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $41.5M -$3.4M -7.56% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $42.4M -$3.34M -7.29% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $43.2M -$3.3M -7.09% Dec 31, 2022 10-K 2024-02-28
Q3 2022 $44.1M -$3.15M -6.67% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $44.9M -$3.52M -7.26% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $45.7M Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $46.5M -$469K -1% Dec 31, 2021 10-K 2023-02-28
Q3 2021 $47.2M Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $48.4M Jun 30, 2021 10-Q 2021-08-12
Q4 2020 $47M Dec 31, 2020 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.